News

Updates from Inflexa

Conferences, announcements, and the latest from our team.

Inflexa and Genomate Health partner to investigate cancer drug response

Inflexa and Genomate Health have begun a research collaboration to investigate why some cancers respond to therapy differently than their molecular profiles predict. Genomate's computational reasoning defines biologically meaningful patient cohorts; Inflexa reads the transcriptomic, proteomic, and other omics layers to surface signals that genomics alone can miss.

announcement

Bruce Press joins Inflexa as Strategic Business Development Advisor

Bruce Press joins Inflexa as Strategic Business Development Advisor. More than 30 years building and commercializing enterprise life science platforms across bioinformatics, advanced computing, and AI for drug discovery. Fluent in the science, the technology, and the business of getting innovation adopted inside big pharma.

announcement

Inflexa joins the BioRN Life Science Cluster

Inflexa has joined the BioRN Life Science Cluster, one of Germany's strongest life science ecosystems, centered on the Rhine-Neckar region and Heidelberg and connecting companies, academia, startups, and investors in translational science.

perspective

The Best Hypothesis About Lung Cancer Might Come From Astronomy

How analogical reasoning in Inflexa surfaced five Tier-1-worthy hypotheses about lung squamous cell carcinoma, none of them from an oncology paper. A worked example on a 4,316-sample lung RNA-seq compendium, reasoning from audio signal processing, linguistics, astronomy, statistical physics, and cybersecurity.

case study

From AEMS plate to clinic: what 320 compounds taught us about CYP2D6 translational risk

Re-analyzing the Ginkgo Datapoints GDPsm1 320-compound panel on an Echo-MS / QQQ-6500 AEMS platform, then layering PharmGKB CPIC evidence and openFDA FAERS disproportionality signals. The platform is technically clean (ρ = 0.977 solubility, ρ = 0.975 IC50, 77% within 2-fold vs literature HLM) and recovers the canonical CYP2D6 pharmacophore, but in-vitro IC50 is statistically decoupled from clinical-evidence and pharmacovigilance axes.

case study

From Postprandial Muscle Biopsy to Druggable Node: a translational re-read of GSE231509

Re-analysing Makhnovskii 2023's 21-subject paired vastus lateralis MMTT cohort: replicating the ERBB3/MET/KIT module, extracting a graded metabolic divergence and a 12-feature biomarker panel (AUC 0.985-0.993), and turning the receptor-level finding into a ranked druggability list led by MET (0.792), ERBB3 (0.766), KIT (0.659), all Tier-1 approved.

case study

Re-reading a 2018 melanoma single-cell atlas with a translational lens: five tier-1 anti-PD-1 combinations

Re-analysing the Jerby-Arnon GSE115978 melanoma atlas under an exclusion-axis reframing: cross-method convergence on the cold-tumour programme, 309 enriched LR pairs in resistance contexts, and a safety-filtered shortlist of five anti-PD-1 combinations after CDK4/6i and ET-axis demotion.

case study

From 406 compounds to 26 translational leads: an end-to-end DRUG-seq dose-response decoder

Rebuilding the analytical pipeline on Ginkgo Datapoints' GDPx4 DRUG-seq screen (406 compounds × 6 doses in HEK293) into 26 Tier-1 leads, 75 novel-MoA hypotheses, and a structural blind spot for cytostatic compounds.

case study

When the Headline Isn't the Whole Paper: Re-Mining an NHP Obesity / T2D Atlas

Re-analysing Zhang et al.'s 22-animal cynomolgus obesity/T2D atlas under a forbidden-target constraint: surfacing 19 novel both-modality candidates on V-ATPase / nuclear-pore / UPS axes, a GDF15→RET adipose-liver hypothesis, and a left-ventricle proteostatic discordance signature.

event

Hands-on Workshop at Babeș-Bolyai University

Inflexa runs a 3-hour hands-on workshop with the Faculty of Biology and Geology: from biological question to PubMed-grounded evidence chain. Friday, May 8, Cluj-Napoca.

case study

From Confounded Cohort to Druggable Hypotheses: A Translational Deep-Dive into Pediatric UC Non-Response

Re-analysing the PROTECT inception cohort (n=206 pediatric UC) with rigorous causal inference, multi-layer mechanism recovery, and directionality-aware tractability triage. Three actionable programmes, one major disqualification, and a novel anti-CXCL13 target.

case study

From a NASH Liver Atlas to a Chemistry-Aware Repurposing Hypothesis

How an integrated transcriptomics + cheminformatics pipeline turned 57 liver biopsies and 822 toxicogenomics profiles into a testable drug hypothesis, and surfaced its own caveats.

event

Cambridge Cheminformatics Meeting: Agents, Chemical Space Docking, QM Scoring

Radu Tanasa presents on agentic analysis and structured evidence for target validation at the Cambridge Cheminformatics Meeting. April 22, hybrid at CCDC Cambridge.

Have something to share?

Reach out if you'd like to collaborate on an event, webinar, or publication.